Merck KGaA (MKGAF)
OTCMKTS · Delayed Price · Currency is USD
155.74
+3.42 (2.25%)
At close: Feb 18, 2026
Merck KGaA Revenue
Merck KGaA had revenue of 5.32B EUR in the quarter ending September 30, 2025, with 0.99% growth. This brings the company's revenue in the last twelve months to 21.27B, up 1.47% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.27B EUR
Revenue Growth
+1.47%
P/S Ratio
2.62
Revenue / Employee
341.18K EUR
Employees
62,346
Market Cap
65.31B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
| Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
| Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
| Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
| Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 34.87M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Merck KGaA News
- 6 days ago - Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson - Investor's Business Daily
- 6 days ago - Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor' - Benzinga
- 4 weeks ago - Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 5 weeks ago - Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 2 months ago - Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA - Investor's Business Daily
- 2 months ago - Thin-Film Electrode Market worth $0.97 billion by 2030 at 11.3%, says MarketsandMarkets™ - Benzinga
- 2 months ago - Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case - WSJ